Reprint

Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation

Edited by
June 2022
346 pages
  • ISBN978-3-0365-4532-5 (Hardback)
  • ISBN978-3-0365-4531-8 (PDF)

This book is a reprint of the Special Issue Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
perfusion estimation; temperature monitoring; conductivity reconstruction; systems medicine; immune system in silico; perceptron; antigen pattern; danger signal; fractionation; immune response; head and neck cancer; hyperthermia; reirradiation; treatment outcome; hyperthermia; hyperthermia treatment planning; adaptive planning; temperature optimization; low-middle-income group countries; cancer; hyperthermia; radiotherapy; chemotherapy; recurrent breast cancers; cervical cancer; head and neck cancers; cost-effective; meta-analysis; hyperthermia; intensity-modulated radiotherapy; prostate cancer; thermal dose; hyperthermia; thermometric parameters; preclinical data; clinical evidence; modulated electro-hyperthermia; abscopal effect; locally advanced cervical cancer; resource-constrained setting; radiosensitiser; rectal cancer; hyperthermia; chemoradiotherapy; tumour control; loco-regional hyperthermia; oncology; modulated electro-hyperthermia; cellular selection; bioelectromagnetics; complexity; immune-effects; moderate hyperthermia; deep hyperthermia; radiative hyperthermia; radiotherapy; patterns of care; reimbursement; regional hyperthermia; rectal cancer; neoadjuvant chemoradiation; survival; hyperthermia; induced; brachytherapy; prostatic neoplasms; interstitial hyperthermia; treatment plan optimization; prostate; thermoradiotherapy; linear quadratic model; biological modeling; thermal dosimetry; hypoxia; hyperthermia; radiation therapy; reoxygenation; perfusion; oxygen consumption rate; local tumor control; biomarker; hyperthermia; radiotherapy; immune phenotype; hyperthermia treatment sequence; breast cancer; immune checkpoint molecules; dendritic cell activation; n/a